LexDanaLexDanabeta
Inventor

Xiao Chen

Inventor
Edison, NJ, US

Overview

46→
Patents
1998–2020
Patent span
Human necessities
Primary field (CPC A)

Patents· 46 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C07Dprimary
C07DHeterocyclic compounds34%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations30%
A61KPreparations for medical, dental or toiletry purposes21%
C07KPeptides7%
C07CAcyclic or carbocyclic compounds3%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium2%
C04BLime, magnesia1%
C07BGeneral methods of organic chemistry1%
C07HSugars1%
Y02ATechnologies for adaptation to climate change1%
PatentTitleYear
10,836,706Bacterial efflux pump inhibitors202010,588,898Opioid receptor ligands and methods of using and making same202010,519,157Deuterated compounds for treating Fabry, Gaucher, Parkinson's and related diseases and conditions, and compositions and methods thereof20199,849,119Opioid receptor ligands and methods of using and making same20179,642,842'Opioid receptor ligands and methods of using and making same'20179,534,017'Beta-arrestin effectors and compositions and methods of use thereof'20179,469,615'Quinoxalines and AZA-quinoxalines as CRTH2 receptor modulators'20169,309,234'Opioid receptor ligands and methods of using and making same'20169,044,469'Opioid receptor ligands and methods of using and making same'20158,993,511'β-arrestin effectors and compositions and methods of use thereof'20158,946,142'Beta-arrestin effectors and compositions and methods of use thereof'20158,835,488'Opioid receptor ligands and methods of using and making same'20148,809,260'β-arrestin effectors and compositions and methods of use thereof'20148,796,204'β-arrestin effectors and compositions and methods of use thereof'20148,598,158'Fused tricyclic compounds for the treatment of inflammatory disorders'20138,486,885'β-arrestin effectors and compositions and methods of use thereof'20138,283,360'Bicyclic heterocyclic derivatives and methods of use thereof'20127,956,189'Maleate, tosylate, fumarate and oxalate salts of 5-(1-(S)-amino-2-hydroxyethyl)-N-[(2,4-difluorophenyl)-methy]-2-[8-methoxy-2-(triflouromethy)-5-quinoline]-4-oxazolecarboxamide and preparation process therefore'20117,763,623'Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia'20107,750,015'Nitrogen-containing heterocyclic compounds and methods of use thereof'20107,737,155'Nitrogen-containing heterocyclic compounds and methods of use thereof'20107,723,342'Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia'20107,547,782'Met kinase inhibitors'20097,511,062'Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors'20097,439,246'Fused heterocyclic kinase inhibitors'20087,354,922'Bridged ring NK1 antagonists'20087,211,671'Substituted 1,3-dihydro-imidazol-2-one and 1,3-dihydro-imidazol-2-thione derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)'20077,173,031'Pyrrolotriazine kinase inhibitors'20077,160,856'α-O-linked glycoconjugates, methods of preparation and uses thereof'20076,995,181'Modulators of the glucocorticoid receptor and method'20066,962,938'Spiro-cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α converting enzyme (TACE)'20056,825,215'1,1-disubstituted cyclic inhibitors of matrix metalloproteases and TNF-'20046,740,649'Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF- converting enzyme (TACE)'20046,720,329'Spiro-cyclic -amino acid derivatives as inhibitors of matrix metalloproteases and TNF- converting enzyme (TACE)'20046,660,714'-O-linked glycoconjugates, methods of preparation and uses thereof'20036,635,630'Selective neurokinin antagonists'20036,436,928'Selective neurokinin antagonists'20026,172,205'Synthetic process toward total synthesis of eleutherobin and its analogues and uses thereof'20016,051,575'Piperazino derivatives as neurokinin antagonists'20005,981,520'Piperazino derivatives as neurokinin antagonists'19995,968,929'Piperazino derivatives as neurokinin antagonists'19995,892,039'Piperazino derivatives as neurokinin antagonists'19995,869,488'Piperazino derivatives as neurokinin antagonists'19995,798,359'Piperazino derivatives as neurokinin antagonists'19985,795,894'Piperazino derivatives as neurokinn antagonists'19985,719,156'Piperazino derivatives as neurokinin antagonists'1998

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1998–2011Patents assigned to SCHERING CORP (17)· patent assignee history
1998–2016Based in Edison, NJ, US· patent location history
2003–2007Based in Newark, DE, US· patent location history
2004–2009Patents assigned to BRISTOL MYERS SQUIBB CO (6)· patent assignee history
2005–2020Based in Furlong, PA, US· patent location history
2012–2016Patents assigned to CHEN XIAO (3)· patent assignee history
2013–2020Patents assigned to TREVENA INC (12)· patent assignee history
2013–2015Patents assigned to CHEN XIAO-TAO (3)· patent assignee history
2019Based in Princeton, NJ, US· patent location history
2020Based in Monmouth Junction, NJ, US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
SCHERING CORP171998–2011
TREVENA INC122013–2020
BRISTOL MYERS SQUIBB CO62004–2009
CHEN XIAOself32012–2016
CHEN XIAO-TAOself32013–2015
Locations
LocationPatentsSpan
Edison, New Jersey, US201998–2016
Furlong, Pennsylvania, US172005–2020
Newark, Delaware, US62003–2007
Monmouth Junction, New Jersey, US12020
Princeton, New Jersey, US12019